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Abstract 
Background 
International guidelines on management of hypertension recommend any major 
classes of antihypertensive drugs.  However the low prescribing rate of thiazides has been 
attributed to concerns about electrolyte disturbances and studies between 
antihypertensive drug classes and hyponatremia/hypokalemia among Chinese patients 
were scarce. 
 
Methods 
From clinical databases we included 2,759 patients who received their first-ever 
antihypertensive monotherapy from January 2004 to June 2007 in a large Territory of 
Hong Kong. We studied the plasma sodium and potassium levels 8 weeks after 
prescriptions and factors associated with hyponatremia and hypokalemia by multivariable 
regression analyses. 
 
Results 
Among major antihypertensive drug classes, thiazide users had the lowest sodium level 
(139.6 mEq/L, 95% C.I. 139.3, 140.0, p<0.001) and patients prescribed calcium channel 
blockers ([CCB] 3.92 mEq/L, 95% C.I. 3.89, 3.95) or thiazide diuretics (3.99 mEq/L, 
95% C.I. 3.93, 4.04) had the lowest potassium levels (p<0.001).  Multivariate analysis 
reported advanced age (> 70 years, OR 7.49, 95% C.I. 2.84, 19.8, p<0.001), male gender 
(OR 2.38, 95% C.I. 1.45, 3.91, p<0.001) and thiazide users (OR 2.42, 95% C.I. 1.29, 4.56, 
p=0.006) were significantly associated with hyponatremia, while RAS (OR 0.31, 95% C.I. 
 2
0.13, 0.73, p=0.008) and β-blockers (OR 0.35, 95% C.I. 0.23, 0.54, p<0.001) users were 
less likely to present with hypokalemia.  However, the proportions having normonatremic 
(95.1%) and normokalemic (89.4%) levels were high. 
 
Conclusions 
In view of the low prevalence of hyponatremia and hypokalemia associated with 
thiazides, physicians should not be deterred from prescribing thiazide diuretics as first-
line antihypertensive agents as recommended by most international guidelines. 
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Introduction 
Thiazide diuretics have been recommended by international guidelines as first-line agents 
in the management of hypertension, including the seventh report of the Joint National 
Committee1 and the National Institute of Clinical Excellence2. However, thiazide 
diuretics could induce metabolic side effects including hyponatremia and hypokalemia3, 4, 
and the majority of patients admitted to hospitals due to electrolyte disturbances can be 
attributed to diuretic use5. This has recently been shown to deter physicians from 
prescribing thiazides to Chinese patients6. 
 
The majority of these reports were conducted in Caucasian countries and electrolyte 
profiles among Chinese hypertensive patients on thiazides have been scarce and small-
scaled7. Ethnicity is associated with different pharmacological outcomes of 
antihypertensive agents and even small ethnic differences may bear substantial health 
resource implications8. 
 
The present study examined the effect of antihypertensive drug classes on 
hyponatremia/ hypokalemia among ethnic Chinese, and evaluated the associated factors 
of these electrolyte disturbances.  We tested the hypothesis that the likelihood of 
hyponatremia and hypokalemia after antihypertensive prescriptions were similar among 
patients prescribed major antihypertensive classes.  
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Methods 
Data source 
The Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority, 
Hong Kong consists of all patient records in public clinic visits since 2000. It captures 
patients’ demographics, clinical information including diagnoses, prescription details and 
laboratory investigation results in every out-patient consultation. One of the major 
functions of CDARS is research9. It is the single portal of information entry in the public 
sector, and is a comprehensive record which allows cross-referencing when patients visit 
a different clinic.  Also, drug prescription details are doubly checked by pharmacist 
professionals and any amendments were recorded in the electronic patient record. In 
addition to these good practices this database has been evaluated and found to have a 
high level of completeness with respect to demographic data (100%) and prescription 
details (99.98%)10. The present study included Hong Kong residents in the New Territory 
East Cluster, which has a population of around 1.3 million. It is further divided into 3 
separate regions, namely Shatin, Tai-Po and the North District, from the most urbanized 
to the most rural regions respectively. Their median monthly household incomes in 2006 
were comparable to the Hong Kong-wide figure of US$2,240. These three regions have 
similar median ages (38-39 years), comparable with the median age of 39 years for Hong 
Kong11. 
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Subjects 
Patients who newly attended the public primary care practice, coded by physicians with 
International Classification of Primary Care (ICPC) K86 [uncomplicated hypertension] 
and who were prescribed a single antihypertensive agent as the first-ever antihypertensive 
pharmacotherapy in the public sector during January 2004 to June 2007 were included in 
a retrospective manner. Only patients who had their plasma sodium and potassium levels 
checked 4 to 16 weeks after the prescription were included. Exclusion criteria included 
subjects having concomitant cardiovascular factors or clinical conditions which could 
confound antihypertensive prescription choice, identified by the respective ICPC codes 
(see Box 1). Also, patients discontinued or switched their drug prescription or received 
sodium or potassium supplements before electrolyte measurements were excluded.  In 
addition, medication adherence was assessed by evidence that the patients attended for 
medication refill at a consultation time where their drug stocks would expire.  We 
calculated the Medication Possession Ratio (MPR) for each patient, defined as the ratio 
of total days of medication supplied (not including the last prescription) to total days in a 
period of time12.  Those with MPR < 0.8 were considered drug non-compliant and 
excluded12.    The minimum follow-up time was 4 weeks in all the eligible cases as 
indicated by our database. 
 
Each patient was classified into one drug group according to the prescription. These 
include β-blockers (BBs), thiazide diuretics, Calcium Channel Blockers (CCBs), drugs 
acting on the renin angiotensin system (RAS) and others (including α-blockers, 
potassium-sparing and other diuretics, vasodilators and combination therapy).  We 
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evaluated the dosage of each prescription qualitatively as “low”, “medium” or “high” 
according to standard drug formulary.  
 
Outcomes Variables, associated factors and statistical analysis 
We evaluated the mean plasma Na/K levels and proportions of patients having low (Na < 
135 mEq/L; K < 3.4 mEq/L), normal (Na 136-147 mEq/L; K 3.5-5.1 mEq/L) and high 
(Na > 148 mEq/L; K > 5.2 mEq/L) levels among the various drug classes. We reported 
the glomerular filtration rate (GFR) as estimated by the Cockcroft-Gault formula13.  We 
divided estimated GFR into tertiles and compared the proportion of hyponatremic vs. 
normonatremic patients belonging to each of the tertiles; and similarly for hypokalemic 
and normokalemic patients.  Independent predictors and covariates include patients’ age, 
gender, payment status (fee waivers vs. payers; each consultation costs US$5.77), district 
of residence, estimated GFR (in tertiles), and the antihypertensive drug classes prescribed 
(thiazide diuretics, BB, CCB, RAS).  The “other” drug group was excluded from the 
multivariate analysis since it contained diuretics and combination therapy, which usually 
consisted of thiazide. 
 
For descriptive analysis student’s t-tests and χ2 tests were used to compare continuous 
and categorical variables respectively. In multivariate analyzes, we entered all the 
variables listed above into the regression equations with hyponatremia and hypokalemia 
as two separate outcome variables.  Drug classes included thiazide diuretics, BB and 
CCB with RAS as a reference group.  Since there are significant differences between 
districts with respect to antihypertensive prescribing, we conducted sensitivity analyzes 
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where district of residence was included and then excluded as an independent variable, 
respectively, to avoid over-controlling of covariates. All p<0.05 were regarded as 
statistically significant.  
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Results 
We included 2,759 eligible patient records, with a mean age of 63.6 years (95% C.I. 63.4, 
64.5) (Table 1). The CCB group was the eldest and had the highest proportion of male 
patients and the BB group was the youngest and had the lowest proportion of male 
patients.  Their electrolyte levels were measured approximately 8 weeks after 
prescriptions and these periods were statistically similar among antihypertensive drug 
classes (p=0.06). From the drug formulary we judged that > 90% of antihypertensive 
prescriptions were of standard dosage (i.e. medium dose), and the proportion of 
prescription dosage being medium when the major drug classes were compared showed 
no significant differences (p=0.42) (Table 2).  Unreliable sodium and potassium levels 
were reported in 85 and 126 patients respectively due to lipemic or hemolytic blood 
samples. For all patients, the mean sodium and potassium levels were 140.0 mEq/L (95% 
C.I. 139.9, 140.1) and 3.99 mEq/L (95% C.I. 3.97, 4.01) respectively. Among the four 
major antihypertensive drug classes, thiazide users had the lowest sodium levels, whereas 
CCB and thiazide had the lowest potassium levels.  Users of β-blockers and RAS had 
higher GFR than other drug classes (p<0.001) (Table 2).  Only one patient had 
hypernatremia, and the proportion of patients having abnormal sodium and potassium 
levels were both low (3.9% and 10.6% respectively, Table 2).  
 
We compared the clinical characteristics of patients having hyponatremia or hypokalemia 
with patients with normonatremia and normokalemia respectively. Hyponatremic patients 
and hypokalemic patients were significantly older than normonatremic and 
normokalemic patients, respectively (Table 3).  Comparison between hyponatremic or 
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hypokalemic patients with normonatremic and normokalemic patients respectively 
according to gender, payment status, district of residence and service types of clinics 
were all statistically insignificant.  Among all drug classes, thiazide users had higher 
proportions of hyponatremia than normonatremic patients, while CCB and thiazide users 
had higher proportions of hypokalemia than normokalemic patients (Table 3).  When 
divided into tertiles, the estimated GFR among hyponatremic patients was significantly 
lower than normonatremic patients (p<0.001) whereas no difference in GFR was reported 
between hypokalemic and normokalemic patients (p=0.10) (Table 3).  
 
Two separate, unconditional binary logistic regression analyzes were performed with 
hyponatremia and hypokalemia as outcome variables, respectively, to evaluate the factors 
related to these electrolyte disturbances.  When controlled for covariates, advanced age (> 
70 years) was associated with hyponatremia when compared with patients < 50 years 
(Table 4). Male patients had significantly higher odds of hyponatremia  than females.  
Residence in the North district (the most rural region) was negatively associated with 
hyponatremia or hypokalemia.  Patients with the highest GFR (3rd tertile) were 
significantly less likely to have hyponatremia.  Thiazide users were positively associated 
with hyponatremia; users of RAS and β-blockers were negatively associated with 
hypokalemia.  When district of residence was excluded from the regression analyses, the 
findings remained similar.  
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Discussion 
Major findings 
This study showed that thiazide diuretics had the lowest levels of plasma sodium, while 
CCBs and thiazide diuretics had the lowest levels of plasma potassium approximately 8 
weeks after the first-ever antihypertensive prescription when compared to other drug 
classes, but the absolute magnitude of differences were minimal. From multivariate 
analyzes advanced age, male gender and thizide user were positively associated with 
hyponatremia, while RAS and β-blockers were less likely to present with hypokalemia 
when compared with CCB.  However, the proportions of patients having these electrolyte 
disturbances were not high. 
 
Interpretation and relationship with literatures 
A previous study in UK general practices reported a higher proportion of hyponatremia 
(13.7%) and hypokalemia (8.5%) among thiazide users14. The same study also reported 
that increased age (> 70 years) was significantly associated with hyponatremia, and that 
hypokalemia was associated with thiazide use. In ethnic groups other than Chinese, 
thiazides have been shown to cause hypokalemia, and potassium levels have been shown 
to be linearly correlated with blood pressure levels15.  Another study in the US has 
identified a positive association between thiazide use and symptomatic hyponatremia 
requiring hospital admission16. Among Chinese patients, there is one study evaluating 
prescriptions of diuretics in two out-patient clinics and concluded that diuretic use was 
associated with hypokalemia17. This study demonstrated that advanced age was 
independently related to hyponatremia.  It has been recognized that elderly women could 
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have expanded fluid volume after increased fluid intake but decreased ability to excrete 
free water, which might explain the higher risks of hyponatremia among the elderly18. 
It is unknown why male patients and residents in rural districts had significantly different 
odds of presenting with these electrolyte disturbances from published literatures, where 
the underlying reasons remained to be explored. 
In addition, the proportion of hyponatremic in hypokalemic patients (15.5%) was greater 
than normonatremic patients (9.1%) (p=0.02), highlighting this as a possible moderator 
of medication effect.  It is consistent with the fact that potassium depletion causes a water 
shift from the intracellular space to the extracellular space and exchangeable potassium is 
hence a determinant of serum Na concentration. 
Also, despite the lowest sodium level among thiazide users and lowest potassium levels 
among CCB users, and that multivariate regression analyzes showed that some drug 
classes were significantly associated with hyponatremia/hypokalemia, these absolute 
differences with the mean sodium and potassium values of all patients, respectively, were 
minimal (0.4 mEq/L and 0.07 mEq/L respectively). Since we included a large sample 
from the whole Territory our results may be more representative of hypertensive patients 
than previous studies. In addition, the inclusion of antihypertensive drug naïve patients 
with uncomplicated hypertension only without concomitant cardiovascular factors; drug 
regimen changes; or sodium and potassium supplements provides a relatively 
uncontaminated sample for evaluating the pharmacologic effects of antihypertensive 
agents.  However, the lower potassium levels among CCB users remain unexplained by 
current published literatures, while on the contrary CCBs such as verapamil and 
 12
nifedipine, at pharmacologic doses, have been proposed to block aldosterone production 
causing hyperkalemia rather than hypokalemia19. 
 
Limitations of the present study 
Among patients newly prescribed antihypertensive agents, we have included only those 
with electrolyte measured 4-16 weeks after their first-ever prescriptions. However, the 
basic demographic characteristics between this group and all patients were statistically 
similar regarding age (63.3 vs. 64.3 years, p=0.18; gender (female 55.6% vs. 56.8%, 
p=0.18; district of residence (residents in most urbanized areas 5.9% vs 5.6%, p=0.40) 
and the types of clinics attended (care under FMSC 8.0% vs. 8.7%, p=0.20).  
Nevertheless, we only studied electrolyte abnormalities 8 weeks after drug prescriptions 
and patients had uncomplicated hypertension only, therefore the applicability of these 
findings to patients with multi-comorbidities should be cautious.  
We have included Chinese patients in this study and it is well recognized that ethnicity is 
an important factor affecting the pharmacologic actions of antihypertensive drugs8, hence 
these findings might not be generalizable to patients of other races. In addition, baseline 
electrolyte levels were not available for comparison among drug classes. Furthermore, we 
evaluated risk-association but not cause-and-effect relationship, which should be more 
appropriately addressed by a prospective study.  A more comprehensive evaluation 
should include dietary surveys on fruit and vegetable intake which had significant 
bearings on plasma electrolyte levels. 
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Implications to clinical practice 
Translated into clinical practice, male patients with advanced age should have their 
sodium levels monitored more closely. Physicians should not be deterred from 
prescribing thiazide. Some caution however is needed in prescribing thiazide and CCBs 
since the prevalence of hypokalemia (11.8% and 12.8% respectively) is still not 
negligible, especially when hypokalemia also causes resistant hypertension and can 
induce salt sensitivity.  Similar studies comparing the odds of dyslipidemia and impaired 
fasting glucose from users of antihypertensive prescriptions reported no significant 
differences among antihypertensive drug classes20-21.  The present study adds further 
“real-life” evidence supporting the use of the major antihypertensive drug classes as 
suitable first-line prescription in the initiation and maintenance of hypertension 
management as recommended by most international guidelines. 
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Box 1 Exclusion criteria for patients coded with the following International 
Classification of Primary Care (ICPC) code 
 
K87     Complicated hypertension 
T90    Diabetes mellitus  
T901    Impaired glucose tolerance  
T92    Gout  
T93    Lipid disorder  
K90, K91    Stroke and cerebrovascular accident   
K74, K76    Ischemic heart diseases  
K75     Acute myocardial infarction  
K77, K84, K99  Heart failure and heart diseases  
R79, R95, R96  Chronic obstructive pulmonary diseases, asthma  
D97    Cirrhosis/other liver disease  
D11    Diarrhea   
D10    Vomiting  
U14, U88, Y85, U78, Y79  Urological conditions  
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Table 1: Patient characteristics (N=2,759)   
 
 β-blockers 
(n=633) 
Thiazide 
(n=311) 
CCBs 
(n=828) 
RAS 
(n=140) 
Others** 
(n=847) 
p 
value 
 % % % % %  
Age (years)
<50 
50-59 
60-69 
>70 
 
 
24.8 
32.1 
19.7 
23.4 
 
16.4 
25.1 
23.2 
35.4 
 
15.2 
20.7 
22.7 
41.4 
 
19.3 
28.6 
20.7 
31.4 
 
11.6 
20.0 
21.4 
47.1 
 
<0.001 
 
Mean Age 
(SD)  
(95% CI) 
 
59.2 
(12.8) 
(58.3-60.3) 
63.2 
(12.6) 
(61.8-64.6) 
65.4 
(13.7) 
(66.4-64.3) 
62.4 
(13.8) 
(60.1-64.4) 
66.6 
(13.4) 
(65.7-67.5) 
 
<0.001 
Gender 
Male（%） 
 
 
36.7 
 
40.5 
 
48.8 
 
42.9 
 
47.7 
 
<0.001 
Payment status 
Fee-waivers 
Fee-payers 
 
 
35.9 
64.1 
 
37.0 
67.0 
 
36.7 
63.3 
 
30.0 
70.0 
 
32.7 
62.3 
 
0.26 
District of 
residence 
Shatin 
Taipo 
North 
Others 
 
 
 
39.5 
18.8 
35.4 
6.3 
 
 
 
32.5 
14.5 
47.3 
5.8 
 
 
41.1 
22.0 
32.1 
4.8 
 
 
36.4 
24.3 
33.6 
5.7 
 
 
49.0 
20.1 
24.1 
6.8 
 
 
<0.001 
 
Service type 
General 
FMSC 
Staff clinic 
 
 
89.6 
7.6 
2.8 
 
90.4 
6.1 
3.5 
 
92.5 
5.8 
1.7 
 
87.1 
10.0 
2.9 
 
88.0 
11.0 
1.1 
 
<0.001 
 
Period form 
prescription to 
electrolyte 
measurement 
(weeks)  
 
8.41 
(8.16-8.67) 
7.90 
(7.57-8.23) 
8.45 
(8.24-8.67) 
8.24 
(7.67-8.81) 
8.91 
(8.68-9.14) 
0.06* 
(CCB: Calcium Channel Blockers; RAS: drugs acting on the renin angiotensin system; FMSC: Family Medicine Specialist Clinic.  
The p values represent chi square tests among the different antihypertensive drug classes across variables in that row.  *these p values 
involve comparison of the first four drug groups only. ** including α-blockers (65%), single pill with at least two antihypertensive 
drug component (33.8%), and miscellaneous (1.2%; potassium-sparing diuretics and vasodilators) 
 
 
 
 
 
 19
 
 
Table 2: Electrolyte and renal function by antihypertensive drug groups 
 
 β-blocker 
(n=606) 
Thiazide 
      (n=306) 
CCBs 
(n=801) 
RAS 
(n=136) 
Others* 
(n=826) 
p values
 
 % % % % %  
Dosage 
High 
Medium 
Low 
 
 
0.0 
74.3 
25.7 
 
0.0 
71.2 
28.8 
 
0.0 
72.2 
27.8 
 
0.0 
67.6 
32.4 
 
0.1 
85.3 
14.5 
 
0.42 
Sodium (mEq/l) 
low (< 135) 
normal (136-147) 
high (> 148) 
 
 
3.8 
96.0 
0.2 
 
5.9 
94.1 
0.0 
 
3.7 
96.3 
0.0 
 
5.1 
94.9 
0.0 
 
6.3 
93.7 
0.0 
 
0.53 
Potassium (mEq/l) 
Low (< 3.4) 
Normal (3.5-5.1) 
High (> 5.2) 
 
 
5.0 
93.4 
1.7 
 
11.8 
86.6 
1.6 
 
12.8 
86.6 
0.6 
 
4.4 
95.6 
0.0 
 
9.5 
89.2 
1.3 
<0.001 
Plasma Levels 
(Mean + 95% C.I) 
Sodium (mEq/l) 
 
 
Potassium (mEq/l) 
 
 
140.3 
(140.0-140.5) 
 
4.07 
(4.03-4.10) 
 
 
139.6 
(139.3-140.0) 
 
3.99 
(3.93-4.04) 
 
 
140.2 
(140.0-140.4) 
 
3.92 
(3.89-3.95) 
 
 
 
139.8 
(139.3-140.3) 
 
4.04 
(3.97-4.11) 
 
 
139.7 
(139.5-139.9) 
 
4.00 
(3.96, 4.03) 
 
 
<0.001 
 
 
<0.001 
 
Serum Creatinine 
(mg/dl) 
(95 % C.I.) 
 
 
0.90 
(0.88-0.97) 
 
0.98 
(0.95-1.02) 
 
0.99 
(0.97-1.02) 
 
0.93 
(0.88-0.97) 
 
1.04 
(1.02-1.07) 
<0.001 
Estimated GFR** 
(ml/min)  
(95% C.I.) 
 
84.87 
(82.21-86.63) 
72.26 
(71.61-76.91) 
73.37 
(71.61-75.14) 
78.68 
(75.14-83.10) 
68.95 
(67.19-70.72) 
<0.001 
(CCB: Calcium Channel Blockers; RAS: drugs acting on the renin angiotensin system.  We excluded 85 and 126 
patients with sodium and potassium readings, respectively, regarded as unreliable due to lipemic or hemolyzed samples.  
The p values represent chi square tests among the first four antihypertensive drug classes across variables in that row  
*including α-blockers (65%), single pill with at least two antihypertensive drug component (33.8%), and miscellaneous 
(1.2%; potassium-sparing diuretics and vasodilators) 
**The estimated Glomerular Filtration Rate was derived from the Cockcroft-Gault formula 
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Table 3 Characteristics of hypertensive patients presented with hyponatremia 
and hypokalemia compared to all patients 
 
 Patients with  
Na < 135mEq/L 
(n=130) 
Patients with 
 Na 136-147mEq/L
(n=2543) 
p  
 
Patients with 
K < 3.4 
(n=252) 
Patients with 
K 3.5-5.1mEq/L 
(n=2386) 
p  
Mean Age 
(95% C.I.) 
 
73.2 
(71.0-75.4) 
64.0 
(63.5-64.5) 
<0.001 65.9 
(64.1-67.7) 
64.0 
(63.5-64.5) 
0.03 
 % %  % % 
Gender 
Male 
 
 
51.5 
 
44.5 
 
0.14 
 
40.5 
 
45.2 
 
0.17 
Payment 
Fee-waiver 
Payers 
 
 
39.2 
60.8 
 
34.9 
65.1 
 
 
0.36 
 
34.9 
65.1 
 
 
35.1 
64.9 
 
 
0.95 
District of residence 
Urban areas 
Rural areas 
 
 
 
93.1 
6.9 
 
 
 
94.0 
6.0 
 
 
0.66 
 
 
96.0 
4.0 
 
 
94.1 
5.9 
 
 
 
0.20 
Service types 
General 
FMSC 
Staff clinics 
 
 
93.1 
6.2 
0.8 
 
90.0 
8.0 
2.0 
 
0.43 
 
92.9 
6.3 
0.8 
 
89.8 
8.1 
2.1 
 
0.21 
Drug classes 
β-blockers 
Thiazide 
CCB 
RAS 
 
 
29.5 
23.1 
38.5 
9.0 
 
 
32.9 
16.3 
43.6 
7.3 
 
 
<0.001 
 
17.2 
20.7 
58.6 
3.4 
 
 
34.2 
16.0 
41.9 
7.8 
 
<0.001 
Estimated GFR* 
First tertile 
 (≤63.30 ml/min) 
Second tertile  
(63.31-84.54 ml/min) 
Third tertile  
(≥84.64 ml/min) 
 
 
51.5 
 
29.2 
 
19.2 
 
 
32.4 
 
33.5 
 
34.1 
 
 
<0.001 
 
 
32.9 
 
33.7 
 
33.3 
 
 
33.2 
 
33.4 
 
33.4 
 
 
0.99 
FMSC: Family Medicine Specialist Clinic; CCB: Calcium Channel Blockers; RAS: drugs acting on the renin 
angiotensin system; GFR: Glomerular filtration rate.  The percentages were across rows for drug classes and across 
columns for other variables.  The p values represent student’s t tests (for mean age) and chi square tests (for other 
variables) between the two groups of patients 
*The estimated Glomerular Filtration Rate was derived from the Cockcroft-Gault formula.  GFR is divided into 
tertiles and the figures in the respective row represent the percentages of patients in the column belonging to the 
respective tertile. 
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 Table 4  Factors associated with hyponatremia and hypokalemia among Chinese 
patients on antihypertensive monotherapy 
 
 
 Hyponatremia (Na < 135 mEq/l) 
(n=130) 
Hypokalemia (K < 3.4 mEq/l) 
(n=252) 
 n % cOR  
(95% C.I.) 
p aOR 
(95% C.I.) 
p n % cOR  
(95% C.I.) 
p aOR 
(95% C.I.) 
p 
Age (years) 
< 50 
50-59 
60-69 
> 70 
 
 
12 
9 
14 
95 
 
2.7 
1.4 
2.4 
9.3 
 
1.0 (ref.) 
0.52 (0.22-.24) 
0.90 (0.41-1.95) 
3.69 (2.00-6.80) 
 
 
 
0.13 
0.78 
<0.001 
 
 
1.0 (ref.) 
0.46 (0.15-1.40) 
1.43 (0.51-3.97) 
7.49 (2.84-19.8) 
 
 
0.17 
0.50 
<0.001 
 
41 
54 
42 
115 
 
9.3 
8.5 
7.3 
11.3 
 
1.0 (ref.) 
0.92 (0.60-1.41) 
0.78 (0.50-1.23) 
1.26 (0.86-1.83) 
 
 
 
0.70 
0.28 
0.24 
 
1.0 (ref.) 
0.87 (0.52-1.46) 
0.81 (0.44-1.47) 
1.30 (0.70-2.39) 
 
 
0.60 
0.48 
0.41 
Gender 
Female 
Male 
 
 
63 
67 
 
4.3 
5.6 
 
1.0 (ref.) 
1.33 (0.93-1.89) 
 
 
0.12 
 
1.0 (ref.) 
2.38 (1.45-3.91) 
 
 
0.001 
 
150 
102 
 
10.2 
8.5 
 
1.0 (ref.) 
0.82 (0.63-1.07) 
 
 
0.15 
 
1.0 (ref.) 
0.89 (0.63-1.25) 
 
 
0.50 
Payment 
Fee-waivers 
Fee-payers 
 
 
51 
79 
 
5.4 
4.6 
 
 
1.0 (ref.) 
0.83 (0.58-1.19) 
 
 
0.31 
 
1.0 (ref.) 
1.09 (0.67-1.78) 
 
 
0.73 
 
88 
164 
 
9.4 
9.5 
 
1.0 (ref.) 
1.01 (0.77-1.33) 
 
 
0.95 
 
1.0 (ref.) 
1.16 (0.83-1.63) 
 
 
0.39 
District of 
residence 
Shatin 
Taipo 
North 
Others 
 
 
 
72 
31 
18 
9 
 
 
6.5 
3.7 
2.0 
5.6 
 
 
1.0 (ref.) 
0.91 (0.59-1.40) 
0.30 (0.18-0.51) 
0.86 (0.42-1.75) 
 
 
 
0.66 
<0.001 
0.68 
 
 
1.0 (ref.) 
1.28 (0.74-2.23) 
0.39 (0.20-0.75) 
0.75 (0.22-2.54) 
 
 
 
0.38 
0.005 
0.64 
 
 
139 
51 
52 
10 
 
 
12.7 
7.2 
6.0 
6.5 
 
 
 
1.0 (ref.) 
0.75 (0.53-1.05) 
0.44 (0.32-0.61) 
0.48 (0.24-0.92) 
 
 
 
0.10 
<0.001 
0.025 
 
 
1.0 (ref.) 
0.67 (0.44-1.02) 
0.37 (0.24-0.55) 
0.40 (0.17-0.94) 
 
 
 
0.06 
<0.001 
0.04 
Estimated 
GFR* (ml/min) 
1st  tertile 
(≤63.30) 
2nd  tertile 
(63.31-84.54) 
3rd tertile 
(≥84.64) 
  
 
 
 
67 
 
38 
 
25 
 
 
 
3.8 
 
2.1 
 
1.4 
 
 
 
1.0 (ref.) 
 
0.55 (0.36-0.82) 
 
0.36 (0.22-0.57) 
 
 
 
 
 
0.003 
 
<0.001 
 
 
 
1.0 (ref.) 
 
0.71 (0.40-1.27) 
 
0.35 (0.15-0.80) 
 
 
 
 
 
0.24 
 
0.013 
 
 
 
 
83 
 
85 
 
84 
 
 
 
4.7 
 
4.8 
 
4.7 
 
 
 
1.0 (ref.) 
 
1.02 (0.74-1.41) 
 
1.02 (0.74-1.40) 
 
 
 
 
 
0.89 
 
0.93 
 
 
 
1.0 (ref.) 
 
0.72 (1.12-0.46) 
 
0.60 (1.08-0.34) 
 
 
 
 
 
0.14 
 
0.08 
Drug classes 
CCB 
RAS 
β-blockers 
Thiazide 
 
 
30 
7 
23 
18 
 
 
3.7 
5.1 
3.8 
5.9 
 
 
1.0   (ref.) 
1.40 (0.60-3.24) 
1.01 (0.58-1.76) 
1.61 (0.88-2.93) 
 
 
 
0.44 
0.96 
0.12 
 
1.0 (ref.) 
1.77 (0.74-4.25) 
1.62 (0.90-2.90) 
2.42 (1.29-4.56) 
 
 
0.20 
0.11 
0.006 
 
102 
6 
30 
36 
 
 
12.8 
4.4 
5.0 
11.8 
 
1.0 (ref.) 
0.32 (0.14-0.74) 
0.36 (0.23-0.54) 
0.91 (0.61-1.37) 
 
 
0.005 
<0.001 
0.67 
 
1.0 (ref.) 
0.31 (0.13-0.73) 
0.35 (0.23-0.54) 
1.05 (0.69-1.60) 
 
 
0.008 
<0.001 
0.81 
(cOR: crude odds ratios; aOR: adjusted odds ratios; GFR Glomerular Filtration Rate; FMSC: Family Medicine Specialist Clinic; 
RAS: drugs acting on the renin angiotensin system; CCB: Calcium Channel Blockers.  All the adjusted odds ratios were 
adjusted for Glomerular filtration rate and the variables listed in this table with hyponatremia and hypokalemia as outcome 
variables respectively.  All the percentages were across rows. 
*The estimated Glomerular Filtration Rate was derived from the Cockcroft-Gault formula) 
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